XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3

Revenue (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Net product revenue in United States, and Company's net revenue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30,

​

September 30,

(in thousands)

2024

​

2023

​

2024

2023

Products

​

​

​

​

​

​

​

​

​

​

​

​

UDENYCA

​

$

66,089

​

$

32,967

​

$

159,673

​

$

90,875

CIMERLI

​

​

(1,215)

​

​

40,037

​

​

26,979

​

​

72,939

YUSIMRY

​

​

(152)

​

​

1,360

​

​

7,508

​

​

1,360

LOQTORZI

​

​

5,832

​

​

—

​

​

11,609

​

​

—

Total net product revenue

​

​

70,554

​

​

74,364

​

​

205,769

​

​

165,174

Other revenue

​

220

​

204

​

7,047

​

546

Total net revenue

​

$

70,774

​

$

74,568

​

$

212,816

​

$

165,720

Schedule of Gross Revenues by Significant Customer as a Percentage of Total Gross Revenues

Gross product revenues by significant customer as a percentage of total gross product revenues were as follows:

​	​	​	​	​	​	​	​	​	​	​	​	​
​		Three Months Ended					​	Nine Months Ended
​	​	September 30,					​	September 30,				​
​	​	2024		​	2023	​	​	2024		​	2023
McKesson Corporation		45	%	​	44	%	​	41	%	​	38	%
Cencora (previously known as AmeriSource-Bergen Corporation)		33	%	​	41	%	​	39	%	​	45	%
Cardinal Health, Inc.		21	%	​	13	%	​	18	%	​	15	%

Schedule of Activities and Ending Reserve Balances for Each Significant Category of Discounts and Allowances

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 2024

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2023

​

$

73,953

​

$

121,137

​

$

49,795

​

$

244,885

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

​

727,028

​

​

150,820

​

​

117,299

​

​

995,147

Prior period - increase (decrease)

​

​

(969)

​

​

6,343

​

​

(1,010)

​

​

4,364

Payments and customer credits issued

​

(747,070)

​

​

(159,737)

​

​

(121,332)

​

​

(1,028,139)

Balances at September 30, 2024

​

$

52,942

​

$

118,563

​

$

44,752

​

$

216,257

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Nine Months Ended September 30, 2023

​

Chargebacks

​

​

Other Fees,

​

​

​

​

and Discounts

​

​

​

​

Co-pay

​

​

​

​

​

for Prompt

​

​

​

​

Assistance

​

​

​

(in thousands)

​

Payment

​

Rebates

​

and Returns

​

Total

Balances at December 31, 2022

​

$

42,677

​

$

38,713

​

$

19,113

​

$

100,503

Provision related to sales made in:

​

​

​

​

​

​

​

​

​

​

​

​

Current period

​

387,238

​

​

83,009

​

​

69,362

​

​

539,609

Prior period - increase (decrease)

​

​

(1,375)

​

​

1,540

​

​

4,469

​

​

4,634

Payments and customer credits issued

​

(379,076)

​

(42,097)

​

(55,681)

​

(476,854)

Balances at September 30, 2023 ​ $ 49,464 ​ $ 81,165 ​ $ 37,263 ​ $ 167,892

​

X

- Definition

Schedule of product sales discounts and allowances.

+ References

No definition available.

+ Details

Name:	chrs_ScheduleOfProductSalesDiscountsAndAllowancesTableTextBlock
Namespace Prefix:	chrs_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration